Evidence map›Paper›PMID 42509855›Full record

ReviewBiomolecules2026

Hesperidin and Hesperetin: Epigenetic-Stemness Crosstalk, Antitumor Mechanisms, Preclinical Data and Translation Barriers.

Mengqi Guo, Linxin Shao, Huiqing Yin, Qianrui Kou, Lele Shang, Haixia Guan, Fang Li

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengqi GuoYan'an Medical College, Yan'an University, Yan'an 716000, China.ORCID 0009-0008-2907-750X
Linxin ShaoYan'an Medical College, Yan'an University, Yan'an 716000, China.
Huiqing YinYan'an Medical College, Yan'an University, Yan'an 716000, China.
Qianrui KouYan'an Medical College, Yan'an University, Yan'an 716000, China.
Lele ShangYan'an Medical College, Yan'an University, Yan'an 716000, China.
Haixia GuanYan'an Medical College, Yan'an University, Yan'an 716000, China.
Fang LiYan'an Medical College, Yan'an University, Yan'an 716000, China.

Funding

Education Department of Shaanxi Province 24JK0726National Natural Science Foundation of China 82260530Yan'an Key Research and Development Program Project 2025SLSFGG-124
6 · The paper itself

Abstract

Hesperidin is a natural flavonoid derived from citrus plants, which can be hydrolyzed into hesperetin in vivo. Both compounds have anti-inflammatory, antioxidant and antitumor activities. At present, there is a lack of reviews focusing on the epigenetic regulation of cancer stem cells (CSCs) mediated by hesperidin and hesperetin. This review summarizes the molecular crosstalk between hesperidin/hesperetin and CSCs mediated via three major epigenetic pathways, including direct regulatory effects, indirect modulatory actions, and mechanistic relationships proposed based on scientific hypotheses. We elaborate their effects on inhibiting the self-renewal, invasion and metastasis of CSCs as well as reversing chemoresistance, and analyze the crosstalk between epigenetic networks and classical signaling pathways of CSCs. Furthermore, we discuss the core bottlenecks restricting the clinical transformation of these two compounds and introduce improvement strategies such as nanodelivery systems. Current research is still confronted with problems including CSC heterogeneity and the potential off-target toxicity of drugs. In conclusion, hesperidin and hesperetin may serve as potential candidate agents for epigenetic regulation targeting CSCs, which can offer novel theoretical basis for comprehensive tumor therapy.

Indexed as

Antineoplastic AgentsEpigenesis, GeneticHesperidinNeoplasmsNeoplastic Stem CellsAnimalsHumansSignal TransductionAntineoplastic AgentshesperetinHesperidincancer stem cellsepigenetic regulationhesperetinhesperidin

Identifiers

PMID42509855
PMCPMC13406621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.